Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06584123

Molecular Pituitary Imaging Using 18F-FET PET

The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pituitary Adenoma Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Hypothalamic Diseases Hypothalamic Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms Pituitary Diseases Pituitary Neoplasms Supratentorial Neoplasms

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cambridge University Hospitals

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

Location status: Recruiting

Location contact

Mark Gurnell, PhD FRCP

CONTACT

[email protected]

+44-1223-245151

Mark Gurnell, PhD FRCP

PRINCIPAL_INVESTIGATOR

About this study

Up to 20 patients with pituitary adenomas (PA) who have previously undergone 11C-methionine PET (Met-PET) as part of routine clinical care will undergo 18F-fluoroethyltyrosine PET (FET-PET). Patients with newly diagnosed PA or residual/recurrent pituitary tumours following previous treatment will be eligible for recruitment to the study.

Quantitative and qualitative analyses will be performed to assess whether MET-PET and FET-PET yield comparable findings in patients with newly diagnosed or recurrent PA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant is willing and able to give informed consent for participation in the study
  • Male or female, age 18 or above
  • Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings
  • Previous 11C-Met-PET/CT

Exclusion criteria

  • Inability to give informed consent
  • Pregnancy or suspected pregnancy
  • Inability to lie supine for 30-60 minutes
  • Patient body habitus above scanner dimensions
  • Known allergy to intravenous radiographic contrast agents

Treatment and study plan

18F-Fluoro-ethyl-tyrosine (FET) PET

Diagnostic Test

18F-Fluoro-ethyl-tyrosine PET study of the pituitary

Primary outcomes

  1. Maximum Standardized Uptake Values (SUVmax) over pituitary tumour on each of 11C-methionine and 18F-fluoroethyltyrosine PET scans

    Time frame: 1 day

    Comparison of maximum Standardized Uptake Values (SUVmax) measured over pituitary tumours on each type of PET scan.

Secondary outcomes

  1. Maximum Standardized Uptake Values (SUVmax) over normal pituitary gland and parasellar structures (e.g. cavernous sinuses) on each of 11C-methionine and 18F-fluoroethyltyrosine PET scans

    Time frame: 1 day

    Comparison of maximum Standardized Uptake Values (SUVmax) measured over normal pituitary gland and parasellar structures (e.g. cavernous sinuses) on each type of PET scan.

Study contacts

Contact information is provided by the study sponsor or research team.

James MacFarlane

CONTACT

[email protected]

01223 250882

Sponsors and collaborators

Lead sponsor

University of Cambridge

Other

Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

Registry information

Official study title

Exploring the Potential for 18F-fluoro-ethyl-tyrosine (18F-FET) to Enable Wider Access to Molecular Imaging for Patients With Pituitary Adenomas (FET-pit-PET Study)

Acronym: FET-pit-PET

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 4, 2024
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.